7910 Woodmont Avenue,Suite 1210
Bethesda, Maryland 20814, U.S.A. 
info@mlsvfund.com |   +1 301 298 5455

© 2018  by MASA Life Science Ventures, LP

NEWS

November 6, 2018

Oxford and Manchester, UK – Cytox, a precision medicine company focused on developing solutions to identify individuals most at risk for developing Alzheimer's disease and dementia, today announced the appointment of Antony Hill as Chief Commercial O...

March 21, 2018

Important clinical evaluation of pioneering approach for risk assessment

8 March 2018: Oxford & Manchester, UK. Cytox, an emerging precision medicine leader providing genetic testing for Alzheimer’s disease, is pleased to announce that, in partnersh...

June 18, 2017

Investment will help commercialize Cytox’s services for testing for Alzheimer’s disease and grow Cytox as a leader in this area.

Cytox, an emerging precision medicine leader providing genetic testing for Alzheimer’s disease, has announced that it ha...

July 24, 2016

Combination will identify amyloid-positive subjects more efficiently and help reduce screening failure rates in clinical trials
 

Oxford, United Kingdom - Cytox Ltd, an innovative developer of assays for risk assessment and prediction of dementia, has...

July 22, 2016

Simple blood-based test will help reduce screening failure in clinical trials and assist drug discovery
 

Oxford, United Kingdom - Cytox Ltd, an innovative developer of assays for risk assessment and prediction of dementia, has announced the launch of...

November 11, 2015

Oxford, United Kingdom - Cytox congratulates Professor John Hardy (UCL Institute of Neurology, London) on receiving the $3 million (Ł2 million) Breakthrough Prize in Life Sciences for his pioneering research into the genetic causes of Alzheimer’s dis...

November 3, 2015

SNP profiling approach in Alzheimer’s disease risk assessment to be highlighted at Barcelona meeting

Oxford, United Kingdom - Cytox Ltd, an innovative developer of assays for risk assessment and prediction of dementia, has announced that it will be...

October 13, 2015

Oxford, United Kingdom - Cytox Ltd, an innovative developer of assays for risk assessment and prediction of dementia, has confirmed its participation in the pioneering French INSIGHT study of Alzheimer’s disease (AD). The Cytox proposal, ‘SNP Profili...

September 17, 2015

Milan conference to detail progress towards earlier diagnosis and improving outcomes
 

Oxford, United Kingdom - Cytox Ltd’s CEO, Dr Richard Pither, will be a keynote speaker at UK Trade & Investment’s (UKTI) GREAT Week Life Sciences thought leadership...

July 20, 2015

Oxford, United Kingdom - Cytox Ltd, an innovative developer of assays for risk assessment and prediction of dementia, and Affymetrix (Nasdaq:AFFX), a leading provider of translational research and diagnostic solutions, announce a strategic partnershi...

Please reload

Featured Posts
Please reload

See News By Company
See News By Month
Please reload